Therefore, the MAGE-A4–RAD18 signalling axis may represent an attractive druggable target whose inhibition is innocuous to normal cells but selectively sensitizes cancer cells to intrinsic and therapy-induced DNA damage and replication stress. Here, MAGEA4 is linked to cancer.